The effect of irinotecan for treating small cell lung cancer on express of FGFBP1 and ABCG2

Abstract

Objective To investigate the effect of irinotecan injection on fibroblast growth factor binding protein 1 (FGFBP1) and ABCG2 in patients with small cell lung cancer (SCLC) and the relationship between fibroblast growth factor BP1 and disease progression. Methods 68 patients with small cell lung cancer were randomly divided into two groups: observation group (34 cases) and control group (34 cases). The observation group was irinotecan combined with cisplatin, while the control group was EP regimen (etoposide combined with cisplatin). Two consecutive chemotherapy cycles were used to evaluate the two groups.Peripheral fasting venous blood was collected before and after chemotherapy.After that, the effective rates and express of FGFBP1 and ABCG2 in two groups were analyzed and compared. Results The effective rates of the observation group and the control group were 88.24% and 58.82% (χ2=7.556, P=0.006), respectively.There were no significant difference in serum FGFBP1 and ABCG2 level between the observation group and the control group before chemotherapy (both P>0.05). The serum levels of ABCG2 and FGFBP1 in the observation group were lower than those in the control group before chemotherapy (both P<0.001). The serum level of FGFBP1 and ABCG2 in the control group were lower than that before chemotherapy (both P<0.05). No serious adverse reactions occurred in the observation group and the control group. Conclusions Iritican is safe and effective in the treatment of small cell lung cancer.The mechanism may be can reduce the levels of ABCG2 and FGFBP1 in serum, and this treatment has good clinical effect. Key words: Iritican; Small cell lung carcinoma; Fibroblast growth factor binding protein 1